Related Experiment Video

Updated: Aug 14, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

A randomized trial of a somatostatin analog for preserving beta cell function in children with insulin dependent

J A Grunt1, H al-Hakim, L Willoughby

  • 1University of Missouri-Kansas City School of Medicine, USA.

The Journal of Pediatric Endocrinology
|October 1, 1994
PubMed

Insights

Octreotide treatment in newly diagnosed children with type 1 diabetes mellitus (IDDM) showed no immediate impact on insulin needs or HbA1c. However, it led to preserved beta cell function, indicated by higher C-peptide levels at 6 and 12 months.

Area of Science:

  • Endocrinology
  • Pediatric Diabetes Research
  • Metabolic Disease Studies

Background:

  • Type 1 diabetes mellitus (IDDM) is an autoimmune disease characterized by beta cell destruction.
  • Preserving residual beta cell function is crucial for improving long-term glycemic control and reducing complications in children with IDDM.
  • Early therapeutic interventions aim to protect remaining insulin-producing beta cells.

Purpose of the Study:

  • To investigate the effect of Octreotide, a somatostatin analog, on preserving beta cell function in newly diagnosed children with IDDM.
  • To assess the impact of short-term Octreotide administration on insulin requirements and glycemic control.
  • To evaluate long-term beta cell function using glucagon-stimulated C-peptide levels.

Main Methods:

  • A prospective study involving ten newly diagnosed children with IDDM receiving Octreotide for 21 days post-diagnosis.
  • A control group of ten age-matched children with IDDM receiving standard care.
  • Comparison of insulin requirements, hemoglobin A1c levels, and glucagon-stimulated C-peptide levels at diagnosis, and at 6 and 12 months post-diagnosis.

Main Results:

  • No significant differences were observed in insulin requirements or hemoglobin A1c levels between the Octreotide group and the control group at any time point.
  • The experimental group (Octreotide) showed significant increases in glucagon-stimulated C-peptide levels at six and 12 months post-diagnosis compared to the control group.
  • These findings suggest a potential benefit of Octreotide in preserving beta cell function.

Conclusions:

  • Short-term administration of Octreotide in newly diagnosed children with IDDM may help preserve residual beta cell function.
  • While not impacting immediate glycemic control or insulin needs, Octreotide shows promise for long-term beta cell preservation.
  • Further research is warranted to confirm these findings and explore optimal therapeutic strategies for type 1 diabetes.

More Related Videos

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice06:57

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Published on: April 10, 2026

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...